Treatment of multiple myeloma patients with the CD38 antibody Daratumumab: focus on in vivo effector mechanisms

Jakub Krejcik

Publikation: Bog/antologi/afhandling/rapportPh.d.-afhandlingForskning

OriginalsprogEngelsk
ForlagSyddansk Universitet. Det Sundhedsvidenskabelige Fakultet
StatusUdgivet - 2017

Citer dette

Krejcik, J. (2017). Treatment of multiple myeloma patients with the CD38 antibody Daratumumab: focus on in vivo effector mechanisms. Syddansk Universitet. Det Sundhedsvidenskabelige Fakultet.
Krejcik, Jakub. / Treatment of multiple myeloma patients with the CD38 antibody Daratumumab : focus on in vivo effector mechanisms. Syddansk Universitet. Det Sundhedsvidenskabelige Fakultet, 2017.
@phdthesis{81d8f4a50c36491aa224e96af7f2161a,
title = "Treatment of multiple myeloma patients with the CD38 antibody Daratumumab: focus on in vivo effector mechanisms",
author = "Jakub Krejcik",
year = "2017",
language = "English",
publisher = "Syddansk Universitet. Det Sundhedsvidenskabelige Fakultet",

}

Krejcik, J 2017, Treatment of multiple myeloma patients with the CD38 antibody Daratumumab: focus on in vivo effector mechanisms. Syddansk Universitet. Det Sundhedsvidenskabelige Fakultet.

Treatment of multiple myeloma patients with the CD38 antibody Daratumumab : focus on in vivo effector mechanisms. / Krejcik, Jakub.

Syddansk Universitet. Det Sundhedsvidenskabelige Fakultet, 2017.

Publikation: Bog/antologi/afhandling/rapportPh.d.-afhandlingForskning

TY - BOOK

T1 - Treatment of multiple myeloma patients with the CD38 antibody Daratumumab

T2 - focus on in vivo effector mechanisms

AU - Krejcik, Jakub

PY - 2017

Y1 - 2017

M3 - Ph.D. thesis

BT - Treatment of multiple myeloma patients with the CD38 antibody Daratumumab

PB - Syddansk Universitet. Det Sundhedsvidenskabelige Fakultet

ER -

Krejcik J. Treatment of multiple myeloma patients with the CD38 antibody Daratumumab: focus on in vivo effector mechanisms. Syddansk Universitet. Det Sundhedsvidenskabelige Fakultet, 2017.